Skip to main content
Top
Published in: PharmacoEconomics 12/2010

01-12-2010 | Review Article

A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States

Author: Dr Ifigeneia Mavranezouli

Published in: PharmacoEconomics | Issue 12/2010

Login to get access

Abstract

Economic evaluation of health technologies in the form of cost-utility analysis is increasingly advocated. The most common outcome measure in this type of analysis is the QALY. In order to estimate QALYs, appropriate utility values are required.
The objective of this review was to identify and critique utility values for schizophrenia-related health states. A critical appraisal was performed on utility values for schizophrenia identified in the systematic literature review that informed the economic analysis of the updated edition of the National Institute for Health and Clinical Excellence (NICE) clinical guideline on schizophrenia for England and Wales.
Seven studies reporting utility values for schizophrenia were identified. The studies employed a variety of methods for generating utility values. None of the reported sets of utility values for schizophrenia were generated using the EQ-5D, which is a measure widely used in cost-utility analysis and preferred by NICE. Nevertheless, the EQ-5D may be less sensitive in capturing aspects of health-related quality of life in patients with schizophrenia.
A condition-specific preference-based instrument may be more appropriate than a generic measure to inform cost-utility analyses of interventions for schizophrenia.
Appendix
Available only for authorised users
Literature
1.
go back to reference National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London: NICE, 2008 National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd ed. London: NICE, 2008
3.
go back to reference Russell LB, Gold MR, Siegel JE, et al. The role of costeffectivenessanalysis in health and medicine. JAMA 1996 Oct; 276 (14): 1172–7 Russell LB, Gold MR, Siegel JE, et al. The role of costeffectivenessanalysis in health and medicine. JAMA 1996 Oct; 276 (14): 1172–7
4.
go back to reference Brazier J, Ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press, 2007 Brazier J, Ratcliffe J, Salomon JA, et al. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press, 2007
5.
go back to reference Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005 Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. New York: Oxford University Press, 2005
6.
go back to reference Brooks R. EuroQol: the current state of play. Health Policy 1996 Jul; 37 (1): 53–72 Brooks R. EuroQol: the current state of play. Health Policy 1996 Jul; 37 (1): 53–72
7.
go back to reference Gudex C, Dolan P, Kind P, et al. Health state valuations form the general public using the visual analogue scale. Qual Life Res 1996 Dec; 5 (6): 521–31 Gudex C, Dolan P, Kind P, et al. Health state valuations form the general public using the visual analogue scale. Qual Life Res 1996 Dec; 5 (6): 521–31
8.
go back to reference Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996 Mar-Apr; 5 (2): 141–54 Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996 Mar-Apr; 5 (2): 141–54
9.
go back to reference Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35 (11): 1095–108 Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35 (11): 1095–108
10.
go back to reference National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008 National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE, 2008
11.
go back to reference Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996 Oct; 276 (15): 1253–8 Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996 Oct; 276 (15): 1253–8
12.
go back to reference National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). NICE clinical guideline 82. London: NICE, 2009 [online]. Available from URL: (http://www.nice.org.uk/CG82) [Accessed 2010 Aug 20] National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). NICE clinical guideline 82. London: NICE, 2009 [online]. Available from URL: (http://​www.​nice.​org.​uk/​CG82) [Accessed 2010 Aug 20]
13.
go back to reference National Collaborating Centre for Mental Health. Schizophrenia: the NICE guideline on the core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated ed. Leicester and London: The British Psychological Society and the Royal College of Psychiatrists, 2010 National Collaborating Centre for Mental Health. Schizophrenia: the NICE guideline on the core interventions in the treatment and management of schizophrenia in adults in primary and secondary care. Updated ed. Leicester and London: The British Psychological Society and the Royal College of Psychiatrists, 2010
15.
go back to reference Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia: a West Midlands Development and Evaluation Committee report. Birmingham: University of Birmingham, Department of Public Health and Epidemiology, West Midlands Development and Evaluation Committee, 1998 Cummins C, Stevens A, Kisely S. The use of olanzapine as a first and second choice treatment in schizophrenia: a West Midlands Development and Evaluation Committee report. Birmingham: University of Birmingham, Department of Public Health and Epidemiology, West Midlands Development and Evaluation Committee, 1998
16.
go back to reference Oh PI, LanctÔt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. JMed Econ 2001; 4 (1-4): 137–56 Oh PI, LanctÔt KL, Mittmann N, et al. Cost-utility of risperidone compared with standard conventional antipsychotics in chronic schizophrenia. JMed Econ 2001; 4 (1-4): 137–56
17.
go back to reference Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol 2001 Winter; 8 (4): 199–206PubMed Oh PI, Iskedjian M, Addis A, et al. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a cost-utility analysis. Can J Clin Pharmacol 2001 Winter; 8 (4): 199–206PubMed
18.
go back to reference Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997 Aug; 17 (4): 298–307 Chouinard G, Albright PS. Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. J Clin Psychopharmacol 1997 Aug; 17 (4): 298–307
19.
go back to reference Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores [published erratum appears in Schizophr Res 2005 Dec 1; 80 (1): 135-6]. Schizophr Res 2004 Nov 1; 71 (1): 155–65 Lenert LA, Sturley AP, Rapaport MH, et al. Public preferences for health states with schizophrenia and a mapping function to estimate utilities from positive and negative symptom scale scores [published erratum appears in Schizophr Res 2005 Dec 1; 80 (1): 135-6]. Schizophr Res 2004 Nov 1; 71 (1): 155–65
20.
go back to reference Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996 Jun; 11 (2): 101–8 Revicki DA, Shakespeare A, Kind P. Preferences for schizophrenia-related health states: a comparison of patients, caregivers and psychiatrists. Int Clin Psychopharmacol 1996 Jun; 11 (2): 101–8
21.
go back to reference Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008 Nov; 6: 105 Briggs A, Wild D, Lees M, et al. Impact of schizophrenia and schizophrenia treatment-related adverse events on quality of life: direct utility elicitation. Health Qual Life Outcomes 2008 Nov; 6: 105
22.
go back to reference Rosser R, Cottee M, Rabin R, et al. Index of health-related quality of life. In: Hopkins A, editor. Measures of the quality of life and the uses to which such measures may be put. London: Royal College of Physicians, 1992: 81–90 Rosser R, Cottee M, Rabin R, et al. Index of health-related quality of life. In: Hopkins A, editor. Measures of the quality of life and the uses to which such measures may be put. London: Royal College of Physicians, 1992: 81–90
23.
go back to reference Barton GR, Hodgekins J, Mugford M, et al. Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis. Schizophr Res 2009 Jul; 112 (1-3): 158–63 Barton GR, Hodgekins J, Mugford M, et al. Cognitive behaviour therapy for improving social recovery in psychosis: cost-effectiveness analysis. Schizophr Res 2009 Jul; 112 (1-3): 158–63
24.
go back to reference De Ridder A, De Graeve D. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. Pharmacoeconomics 2009; 27 (1): 69–80PubMedCrossRef De Ridder A, De Graeve D. Comparing the cost effectiveness of risperidone and olanzapine in the treatment of schizophrenia using the net-benefit regression approach. Pharmacoeconomics 2009; 27 (1): 69–80PubMedCrossRef
25.
go back to reference Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics 2008; 26 (4): 341–58PubMedCrossRef Knapp M, Windmeijer F, Brown J, et al. Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-European SOHO study. Pharmacoeconomics 2008; 26 (4): 341–58PubMedCrossRef
26.
go back to reference Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006 May; 10 (17): iii-iv, ix-xi, 1–165 Lewis SW, Davies L, Jones PB, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006 May; 10 (17): iii-iv, ix-xi, 1–165
27.
go back to reference Lenert LA, Rupnow MFT, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes 2005 Sep 11; 3: 57 Lenert LA, Rupnow MFT, Elnitsky C. Application of a disease-specific mapping function to estimate utility gains with effective treatment of schizophrenia. Health Qual Life Outcomes 2005 Sep 11; 3: 57
28.
go back to reference Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006 Dec; 163 (12): 2080–9 Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006 Dec; 163 (12): 2080–9
31.
go back to reference Prieto L, Sacristán JA, Hormaechea JA, et al. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004 Jun; 20 (6): 827–35 Prieto L, Sacristán JA, Hormaechea JA, et al. Psychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patients. Curr Med Res Opin 2004 Jun; 20 (6): 827–35
32.
go back to reference König HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry 2007 Apr; 22 (3): 177–87 König HH, Roick C, Angermeyer MC. Validity of the EQ-5D in assessing and valuing health status in patients with schizophrenic, schizotypal or delusional disorders. Eur Psychiatry 2007 Apr; 22 (3): 177–87
33.
go back to reference Barton GR, Hodgekins J, Mugford M, et al. Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br J Psychiatry 2009 Aug; 195 (2): 170–7 Barton GR, Hodgekins J, Mugford M, et al. Measuring the benefits of treatment for psychosis: validity and responsiveness of the EQ-5D. Br J Psychiatry 2009 Aug; 195 (2): 170–7
34.
go back to reference van de Willige G, Wiersma D, Nienhuis FJ, et al. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res 2005 Mar; 14 (2): 441–51 van de Willige G, Wiersma D, Nienhuis FJ, et al. Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL. Qual Life Res 2005 Mar; 14 (2): 441–51
35.
go back to reference Meijer CJ, Schene AH, Koeter MWJ. Quality of life in schizophrenia measured by the MOS SF-36 and the Lancashire Quality of Life Profile. Acta Psychiatr Scand 2002 Apr; 105 (4): 293–300 Meijer CJ, Schene AH, Koeter MWJ. Quality of life in schizophrenia measured by the MOS SF-36 and the Lancashire Quality of Life Profile. Acta Psychiatr Scand 2002 Apr; 105 (4): 293–300
36.
go back to reference Leese M, Schene A, Koeter M, et al. SF-36 scales, and simple sums of scales, were reliable quality-of-life summaries for patients with schizophrenia. J Clin Epidemiol 2008 Jun; 61 (6): 588–96 Leese M, Schene A, Koeter M, et al. SF-36 scales, and simple sums of scales, were reliable quality-of-life summaries for patients with schizophrenia. J Clin Epidemiol 2008 Jun; 61 (6): 588–96
37.
go back to reference Brazier JE, Roberts J, Deverill M. The estimation of a preference based measure of health from the SF-36. J Health Econ 2002 Mar; 21 (2): 271–92 Brazier JE, Roberts J, Deverill M. The estimation of a preference based measure of health from the SF-36. J Health Econ 2002 Mar; 21 (2): 271–92
38.
go back to reference Brazier J. Measuring and valuing mental health for use in economic evaluation. J Health Serv Res Policy 2008 Oct; 13 Suppl. 3: 70–5 Brazier J. Measuring and valuing mental health for use in economic evaluation. J Health Serv Res Policy 2008 Oct; 13 Suppl. 3: 70–5
39.
go back to reference McCrone P, Patel A, Knapp M, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ 2009 Mar; 12 (1): 27–31 McCrone P, Patel A, Knapp M, et al. A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia. J Ment Health Policy Econ 2009 Mar; 12 (1): 27–31
40.
go back to reference Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol 1997 Feb; 32 (2): 68–75 Chisholm D, Healey A, Knapp M. QALYs and mental health care. Soc Psychiatry Psychiatr Epidemiol 1997 Feb; 32 (2): 68–75
41.
go back to reference Knapp M, Mangalore R. The trouble with QALYs.... Epidemiol Psichiatr Soc 2007 Oct-Dec; 16 (4): 289–93 Knapp M, Mangalore R. The trouble with QALYs.... Epidemiol Psichiatr Soc 2007 Oct-Dec; 16 (4): 289–93
42.
go back to reference Brazier J, Czoski—Murray C, Roberts J, et al. Estimation of a preference—based index from a condition—specific measure: the King’s Health Questionnaire. Med Decis Making 2008 Feb; 28 (1): 113–26 Brazier J, Czoski—Murray C, Roberts J, et al. Estimation of a preference—based index from a condition—specific measure: the King’s Health Questionnaire. Med Decis Making 2008 Feb; 28 (1): 113–26
43.
go back to reference Sundaram M, Smith MJ, Revicki DA, et al. Rasch analysis informed the development of a classification system for a diabetes-specific preference-based measure of health. J Clin Epidemiol 2009 Aug; 62 (8): 845–56 Sundaram M, Smith MJ, Revicki DA, et al. Rasch analysis informed the development of a classification system for a diabetes-specific preference-based measure of health. J Clin Epidemiol 2009 Aug; 62 (8): 845–56
44.
go back to reference Yang Y, Brazier J, Tsuchiya A, et al. Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value Health 2009 Jan; 12 (1): 159–66 Yang Y, Brazier J, Tsuchiya A, et al. Estimating a preference-based single index from the Overactive Bladder Questionnaire. Value Health 2009 Jan; 12 (1): 159–66
46.
go back to reference Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3 (9): i-iv, 1–164 Brazier J, Deverill M, Green C, et al. A review of the use of health status measures in economic evaluation. Health Technol Assess 1999; 3 (9): i-iv, 1–164
47.
go back to reference Bebbington PE, Angermeyer M, Azorin JM, et al. Sideeffects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Sup 2009; 119 (438): 22–8CrossRef Bebbington PE, Angermeyer M, Azorin JM, et al. Sideeffects of antipsychotic medication and health-related quality of life in schizophrenia. Acta Psychiatr Scand Sup 2009; 119 (438): 22–8CrossRef
48.
go back to reference Lee TT, Ziegler JK, Sommi R, et al. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. J Psychiatr Res 2000 May-Jun; 34 (3): 201–10 Lee TT, Ziegler JK, Sommi R, et al. Comparison of preferences for health outcomes in schizophrenia among stakeholder groups. J Psychiatr Res 2000 May-Jun; 34 (3): 201–10
49.
go back to reference Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care 2000 Oct; 38 (10): 1011–21 Lenert LA, Ziegler J, Lee T, et al. Differences in health values among patients, family members, and providers for outcomes in schizophrenia. Med Care 2000 Oct; 38 (10): 1011–21
50.
go back to reference Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003 Sep; 12 (6): 599–607 Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003 Sep; 12 (6): 599–607
51.
go back to reference Shumway M. Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups. Schizophr Bull 2003; 29 (2): 257–66PubMedCrossRef Shumway M. Preference weights for cost-outcome analyses of schizophrenia treatments: comparison of four stakeholder groups. Schizophr Bull 2003; 29 (2): 257–66PubMedCrossRef
52.
go back to reference Brazier J, Akehurst R, Brennan A, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005; 4 (4): 201–8PubMedCrossRef Brazier J, Akehurst R, Brennan A, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005; 4 (4): 201–8PubMedCrossRef
53.
go back to reference Voruganti L-NP, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics 2000 Mar; 17 (3): 273–86 Voruganti L-NP, Awad AG, Oyewumi LK, et al. Assessing health utilities in schizophrenia: a feasibility study. Pharmacoeconomics 2000 Mar; 17 (3): 273–86
Metadata
Title
A Review and Critique of Studies Reporting Utility Values for Schizophrenia-Related Health States
Author
Dr Ifigeneia Mavranezouli
Publication date
01-12-2010
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 12/2010
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/11537300-000000000-00000

Other articles of this Issue 12/2010

PharmacoEconomics 12/2010 Go to the issue

Announcement

Acknowledgement